-
Vista Pharmaceuticals Announces Positive Topline Results from Phase 3 Trial of VPI-1921 for the Treatment of Dry Age-Related Macular Degeneration
Vista Pharmaceuticals Announces Positive Topline Results from Phase 3 Trial of VPI-1921 for the Treatment of Dry Age-Related Macular Degeneration
-
Vista Pharmaceuticals Announces Initiation of Phase 2 Trial of VPI-1921 for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Vista Pharmaceuticals Announces Initiation of Phase 2 Trial of VPI-1921 for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
-
Vista Pharmaceuticals Announces Pricing of Public Offering of Ordinary Shares
Vista Pharmaceuticals Announces Pricing of Public Offering of Ordinary Shares
-
Vista Pharmaceuticals Announces Positive Results from Phase 2 Trial of VPI-1921 for the Treatment of Dry Age-Related Macular Degeneration
Vista Pharmaceuticals Announces Positive Results from Phase 2 Trial of VPI-1921 for the Treatment of Dry Age-Related Macular Degeneration
-
Vista Pharmaceuticals Announces Initiation of Phase 3 Trial of VPI-1921 for the Treatment of Dry Age-Related Macular Degeneration
Vista Pharmaceuticals Announces Initiation of Phase 3 Trial of VPI-1921 for the Treatment of Dry Age-Related Macular Degeneration
-
Vista Pharmaceuticals Announces Positive Results from Phase 2b Study of its Novel Drug, THR-18
Vista Pharmaceuticals Ltd. (Nasdaq: VSTA), a biopharmaceutical company focused on the development and commercialization of innovative therapies for ophthalmic diseases, today announced positive results from a Phase 2b study evaluating the safety and efficacy of THR-18, its novel drug for the treatment of dry eye disease (DED).
-
Vista Pharmaceuticals Strengthens Leadership Team with Appointment of New Chief Medical Officer
Vista Pharmaceuticals Ltd. (Nasdaq: VSTA), a biopharmaceutical company focused on the development and commercialization of innovative therapies for ophthalmic diseases, today announced the appointment of Dr. Howard Scher as its new Chief Medical Officer (CMO).
-
Vista Pharmaceuticals Announces Expansion of Strategic Collaboration with Alcon
Vista Pharmaceuticals Ltd. (Nasdaq: VSTA), a biopharmaceutical company focused on the development and commercialization of innovative therapies for ophthalmic diseases, today announced the expansion of its strategic collaboration with Alcon, a global leader in eye care.
-
Vista Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for THR-687
Vista Pharmaceuticals Ltd. (Nasdaq: VSTA), a biopharmaceutical company focused on the development and commercialization of innovative therapies for ophthalmic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for THR-687, its novel drug for the treatment of dry eye disease (DED).
-
Vista Pharmaceuticals Announces Positive Preclinical Data for THR-420, its Novel Drug for the Treatment of Glaucoma
Vista Pharmaceuticals Ltd. (Nasdaq: VSTA), a biopharmaceutical company focused on the development and commercialization of innovative therapies for ophthalmic diseases, today announced positive preclinical data for THR-420, its novel drug for the treatment of glaucoma.
-
Vista Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Vista Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Vista Pharmaceuticals Announces Dosing of First Patient in Phase 2b Clinical Trial of VPI-2754 for the Treatment of Dry Eye Disease
Vista Pharmaceuticals Announces Dosing of First Patient in Phase 2b Clinical Trial of VPI-2754 for the Treatment of Dry Eye Disease
-
Vista Pharmaceuticals Appoints Dr. Jeffrey Havard as Chief Medical Officer
Vista Pharmaceuticals Appoints Dr. Jeffrey Havard as Chief Medical Officer
-
Vista Pharmaceuticals Announces Closing of $60 Million Public Offering of Common Stock
Vista Pharmaceuticals Announces Closing of $60 Million Public Offering of Common Stock
-
Vista Pharmaceuticals Announces Positive Top-Line Results from Phase 2a Clinical Trial of VPI-2754 for the Treatment of Dry Eye Disease
Vista Pharmaceuticals Announces Positive Top-Line Results from Phase 2a Clinical Trial of VPI-2754 for the Treatment of Dry Eye Disease
-
Vista Pharmaceuticals Appoints New Chief Financial Officer
Vista Pharmaceuticals Ltd. (ASX: VPH) is pleased to announce the appointment of Mr. Mark Coffey as Chief Financial Officer, effective June 5, 2023.
-
Vista Pharmaceuticals Announces Positive Data from Phase 2b Trial of APX3330 in Dry Eye Disease
Vista Pharmaceuticals Ltd. (ASX: VPH) is pleased to announce positive top-line results from its Phase 2b clinical trial evaluating APX3330 in patients with dry eye disease.
-
Vista Pharmaceuticals Provides Corporate Update and Announces Completion of Phase 2b Trial of APX3330 in Dry Eye Disease
Vista Pharmaceuticals Ltd. (ASX: VPH) is pleased to provide a corporate update and announce the completion of its Phase 2b clinical trial evaluating APX3330 in patients with dry eye disease.
-
Vista Pharmaceuticals Announces Positive Phase 2b Data for Vanspring for the Treatment of Dry Eye Disease
Vista Pharmaceuticals today announced positive topline results from its Phase 2b clinical trial evaluating the efficacy and safety of Vanspring for the treatment of dry eye disease.
-
Vista Pharmaceuticals Receives FDA Fast Track Designation for Vanspring for the Treatment of Dry Eye Disease
Vista Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Vanspring for the treatment of dry eye disease.
-
Vista Pharmaceuticals Announces Positive Preclinical Data for VPS301 for the Treatment of Glaucoma
Vista Pharmaceuticals today announced positive preclinical data for VPS301, a novel topical treatment for glaucoma.
-
Vista Pharmaceuticals Announces Positive Preclinical Data from In-Vivo Glaucoma Studies of VPI-1924
Vista Pharmaceuticals Announces Positive Preclinical Data from In-Vivo Glaucoma Studies of VPI-1924
-
Vista Pharmaceuticals Announces Collaboration with University of California, San Diego to Develop Novel Therapeutics for Glaucoma
Vista Pharmaceuticals Announces Collaboration with University of California, San Diego to Develop Novel Therapeutics for Glaucoma
-
Vista Pharmaceuticals Announces Positive Preclinical Data for VPI-1924 in Dry Eye Disease
Vista Pharmaceuticals Announces Positive Preclinical Data for VPI-1924 in Dry Eye Disease
-
Vista Pharmaceuticals Announces Positive Preclinical Data for VPI-1924 in Glaucoma
Vista Pharmaceuticals Announces Positive Preclinical Data for VPI-1924 in Glaucoma
-
Vista Pharmaceuticals Announces Initiation of Phase 2a Clinical Trial for VPI-1924 in Dry Eye Disease
Vista Pharmaceuticals Announces Initiation of Phase 2a Clinical Trial for VPI-1924 in Dry Eye Disease
-
Vista Pharmaceuticals Announces Positive Top-Line Results from VISTA-247 Phase 3 Trial in Wet AMD
Vista Pharmaceuticals Ltd. (ASX: VPH), a clinical-stage ophthalmic pharmaceutical company, today announced positive top-line results from the VISTA-247 Phase 3 trial evaluating the efficacy and safety of VT-247 in patients with wet age-related macular degeneration (wet AMD).
-
Vista Pharmaceuticals to Present at Upcoming Medical Conferences
Vista Pharmaceuticals Ltd. (ASX: VPH), a clinical-stage ophthalmic pharmaceutical company, today announced that it will be presenting at two upcoming medical conferences.
-
Vista Pharmaceuticals Enrolls First Patient in Phase 2b Trial of VT-323 for Dry AMD
Vista Pharmaceuticals Ltd. (ASX: VPH), a clinical-stage ophthalmic pharmaceutical company, today announced that it has enrolled the first patient in a Phase 2b clinical trial of VT-323 for the treatment of dry age-related macular degeneration (AMD).